New Direct Detection Test for Lyme

A new direct test for Lyme disease was announced by Galaxy Diagnostics Inc., the Nanotrap® Urine Test for Lyme Borreliosis.  This is a urine-based Lyme antigen test, that Galaxy states “provides the most sensitive direct detection of Borrelia burgdorferi infection at all stages of the disease.” The test is easily administered through collection of urine; and identifies positive cases missed by CDC-recommended two-tiered testing, reducing concern for false positive results via direct detection of OspA proteins. 

Published data shows that the Nanotrap® Urine Test is very effective for confirmation of early stage Lyme borreliosis in patients with EM rashes. Galaxy states that their unpublished validation data shows that the Nanotrap® Urine Test often confirms active infection in patients with negative CDC recommended Two-Tiered Testing results.

Clinical utility of this test for other presentations of Lyme, including Lyme arthritis, Lyme carditis, and neuroborreliosis, needs further research.

This information is provided by LDA for informational purposes only. The LDA does not recommend or endorse this test but provides it for informational purposes only.  Contact your health care provider for medical advice. 

Galaxy Diagnostics News Release: November 10, 2020

Application of Nanotrap technology for high sensitivity measurement of urinary outer surface protein A carboxyl-terminus domain in early stage Lyme borreliosis